RAPT Therapeutics Presents Positive Phase 2 CSU Data and Outlines Ozureprubart's Path in Food Allergy and Urticaria

summarizeSummary

RAPT Therapeutics presented at the J.P. Morgan Healthcare Conference, detailing positive Phase 2 data for Ozureprubart in Chronic Spontaneous Urticaria and outlining its clinical development strategy for food allergies and future milestones.

check_boxKey Events

• Positive Phase 2 CSU Data

  Ozureprubart demonstrated comparable efficacy and safety to omalizumab in Chronic Spontaneous Urticaria, with sustained efficacy for 16 weeks, supporting a best-in-class profile.

• Food Allergy Trial Progress

  The company initiated a Phase 2b clinical trial for Ozureprubart in food allergy, with topline data anticipated in the first half of 2027.

• Strategic Milestones Outlined

  Key upcoming milestones include initiating a Phase 3 CSU trial in 2H 2026 and further asthma development, positioning Ozureprubart for significant market opportunities.

• Strong Financial Runway

  RAPT Therapeutics is well-funded, with cash projected to last through mid-2028, covering multiple critical clinical milestones.

auto_awesomeAnalysis

The presentation provides a comprehensive update on Ozureprubart (RPT904), highlighting its potential as a next-generation anti-IgE antibody with advantages over existing treatments like omalizumab. Positive Phase 2 data in Chronic Spontaneous Urticaria (CSU) supports its best-in-class profile, with plans for Phase 3 initiation in 2H 2026. The company also initiated a Phase 2b trial for food allergies, with data expected in 1H 2027, targeting multi-billion dollar markets. The projected cash runway through mid-2028, covering these key milestones, provides financial stability. These updates offer significant clarity on the company's pipeline progress and commercial strategy, reinforcing the investment thesis.